DiscoverThe Cancer History Project
The Cancer History Project

The Cancer History Project

Author: Cancer History Project

Subscribed: 4Played: 6
Share

Description

A podcast of oral histories and interviews with the people who have shaped oncology as we know it.
The Cancer History Project is an initiative by The Cancer Letter, oncology's longest-running news publication. The Cancer History Project’s archives are available online at CancerHistoryProject.com.
58 Episodes
Reverse
When Barnett Kramer joined the National Cancer Institute as a young physician in 1986, NCI was in the business of developing cancer screening guidelines. In the 80’s and 90’s, physicians across the country looked to NCI for guidance on the subject.NCI based the guidelines on a consensus, a process which relies in part on anecdote and can be clouded by bias and personal experiences, according to Barry Kramer, former director of NCI’s Division of Cancer Prevention, who pushed NCI to stop publishing guidelines. “In my opinion, [the consensus process] is a statement of benefits without really clear quantification or statement of harms,” said Kramer. “It was very difficult for a patient or a clinician to achieve true informed decision-making if they are only exposed to what the benefits could be without the counterbalancing possibility of the consequences of screening.”Kramer knew there was another way—systematic evidence review—which was utilized by another body gaining traction at the time: The U.S. Preventative Services Task Force. In his mind, NCI’s role is to develop the evidence, not establish guidelines.“I consciously, purposely, got out of the business of guidelines because I wanted to get out of the political atmosphere of guidelines, stick to evidence, and defer to the task force,” Kramer said.By the early 2010s, NCI completely pulled out of guideline-making and deferred entirely to USPSTF.In this episode of The Cancer History Project Podcast, Reporter Sara Willa Ernst sits down with Barry Kramer, former director of NCI’s Division of Cancer Prevention to talk about a time before USPSTF and cancer screening guidelines based on systematic evidence review. As the task force remains sidelined, we now find ourselves in a similar spot—absent a body conducting systematic evidence reviews to inform policy.Under the Trump administration, USPSTF has gone through big changes. Last year, HHS Secretary Robert F. Kennedy, Jr. fired key leaders. Then, in September, he appointed new members who critics say break with the guiding principles of the panel. The task force remains in limbo—having not met for more than a year.The Cancer History Project Podcast is sponsored by City of Hope, the American Society of Clinical Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center.A transcript of this podcast is available, along with an archive of related articles, on the Cancer History Project website: https://cancerhistoryproject.com/article/kramer-nci-screening/
When 34-year-old Keaton Herzer was diagnosed with cholangiocarcinoma, a rare bile duct cancer, he didn’t want to settle for anything less than a cure. “I remember so vividly, the surgeon said, ‘This is actually a very good treatment, we've seen people live up to five years with this device,’” Herzer recalled. “And I remember thinking, ‘Man, you're saying that to me like it's a good thing? I'm supposed to be happy about five years? I'm hoping for 40 more years or more.’”He had a 16-month-old little boy and didn’t want him growing up without a father. Throughout his treatment, he was given bad news time and time again: your tumors aren’t shrinking; this drug is not covered by insurance; you are not a candidate for a liver transplant.But he didn’t take no for an answer. When chemo wasn’t working, he found a treatment that targeted his mutation. He fired his oncologist after repeatedly feeling dismissed and unseen. He challenged insurance denials. “[My wife and I] spent probably four hours or more on the phone with insurance every day for a month,” Herzer said. “Do I wait or do I deplete my entire life savings and pay for these infusions out-of-pocket? I don't want to wait because time is not on my side with this cancer. Anytime I spend waiting, it could mean my cancer grows, it spreads, and then a transplant is off the table completely.“We drained our savings, we paid out of pocket.”One battle after another, Herzer fiercely advocated for himself. Today, Herzer is a liver transplant recipient with no evidence of disease. His son is now 3. In this episode of The Cancer History Project Podcast, Deborah Doroshow, associate professor of medicine at Tisch Cancer Institute at Mount Sinai, sits down with survivor Keaton Herzer in honor of cholangiocarcinoma awareness month. The Cancer History Project Podcast is sponsored by City of Hope, the American Society of Clinical Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center. A transcript of this podcast is available, along with an archive of related articles, on the Cancer History Project website: https://cancerhistoryproject.com/article/keaton-herzer-cholangiocarcinoma/
Michael A. Crane, the medical director of the World Trade Center Health Program Clinical Center of Excellence at Mount Sinai, thought he would be seeing a lot of cases of lung cancer coming into his clinic. “My greatest concern was that they were gonna get lung cancer,” Crane said. He remembers treating 9/11 first responders during the immediate recovery. Workers would put on a mask and the filter would clog up within 30 minutes. The air was thick and impossible to breathe. But 25 years later, an uptick in lung cancer hasn’t really panned out in the data—so far. “Fingers crossed, fingers crossed, it might be off the table,” he said. “But of course, there's no guarantees in life, as in anything else.”In this episode of the Cancer History Project podcast, reporter Sara Willa Ernst sits down with Michael Crane to talk about the surprising twists and turns of treating 9/11 first responders over the past 25 years. He also offers his theory behind why the incidence of lung cancer didn’t spike as expected—an achievement, perhaps one of Crane’s proudest, that the program was able to accomplish. The WTC Health Program was able to reduce smoking among first responders from 20% to just 3%, according to Mount Sinai data.“When I die, and God asks me: ‘What did you do with your life?’ I'm gonna give them that statistic and demand to get into the doors. ‘Open the doors, buddy! Look what I did here,’” Crane said. The Cancer History Project Podcast is sponsored by City of Hope, the American Society of Clinical Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center. A transcript of this podcast is available, along with an archive of related articles, on the Cancer History Project website:  https://cancerhistoryproject.com/article/michael-crane-911/ 
Fran Visco, president of The National Breast Cancer Coalition, sat down with Paul Goldberg, editor and publisher of The Cancer Letter for a special armchair discussion at the NBCC Advocate Leadership Summit in 2022. They discuss the history of NBCC and breast cancer activism, including one of the organization’s top accomplishments: the Department of Defense Breast Cancer Research Program. This came after the “$300 Million More” campaign in 1992, which drew in advocates from all across the country. “We need to do for breast cancer what the AIDS activists are doing for AIDS. Maybe we should all take out our prosthesis and march topless to Congress,” Fran Visco recalled co-founder Susan Love saying in the early days of creating NBCC. “We were really inspired by the AIDS activists.”In the eyes of Visco and her fellow activists, NBCC had waged “war” against breast cancer. “When this administration decided to wage a war, you found $7.5 billion to fund it,” Visco said in a 1992 address to Congress. “Women have declared war on breast cancer and you had better find a way to fund that war.“We will no longer be passive. We will no longer be polite. We can no longer afford to wait while Congress gets around to significant decent funding for breast cancer. We implore you. You must find a way to appropriate the additional $300 million for breast cancer research now. We can accept no less.”The Cancer History Project Podcast is sponsored by City of Hope, the American Society of Clinical Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center.A transcript of this conversation, along with an archive of related content, is available on the Cancer History Project: https://cancerhistoryproject.com/article/fran-visco-tells-the-story-of-nbcc/
If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock. Of the hundreds of scientists Fraumeni mentored, perhaps one of the closest was Stephen J. Chanock, his successor as director of the NCI Division of Cancer Epidemiology and Genetics, who worked with Fraumeni for 25 years. Fraumeni died on June 22. He was 93. Otis Brawley, co-editor of the Cancer History Project and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, interviewed Chanock on the most recent episode of the Cancer History Project podcast. Brawley and Chanock looked back on Fraumeni’s 50-year long career. His contributions to science included co-discovering the Li-Fraumeni syndrome and developing cancer maps, which visualize cancer rate data from every county in the U.S. His work served as a backbone for other major discoveries, such as the two-hit hypothesis by Alfred Knudson and BRCA genes.Fraumeni developed theories around how cancer works and tested them. “The mission statement of DCEG has been to understand the etiology of cancer through epidemiology and genetics as a means to prevention or early intervention,” Chanock said. “That's really the wisdom of Joe Fraumeni who lived that, and really developed the tools, the capabilities, and the workforce to pursue that.”As a result, Fraumeni established a vision of cancer's genetic susceptibility. His observations about diethylstilbestrol raised “a very revolutionary idea” that early exposures could result in precancerous conditions and develop into cancers decades later. The cancer maps added a new attention to cancer caused by environmental exposures. “These patterns were very important, which led to understandings about what was going on post-World War II and [how] certain occupations are associated with select cancers,” Chanock said. “This led to the birth of a whole set of cohorts and case control studies to look at asbestos, smelters, occupational hazards and smokeless tobacco use in the South.” The goal was always to help patients, many of whom had no options at the start of Fraumeni’s career. “What Joe was envisioning was the more we understand, the more we can be honest and explain to our patients who develop cancer or may develop cancer, what we could be done to prevent or decrease that risk,” Chanock said. The Cancer History Project Podcast is sponsored by City of Hope, the American Society of Clinical Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center.A transcript of this conversation, along with an archive of related content, is available on the Cancer History Project: https://cancerhistoryproject.com/article/joseph-f-fraumeni-jr/ 
loading
Comments